Acuitas Investments LLC Reduces Stock Holdings in XOMA Co. (NASDAQ:XOMA)

Acuitas Investments LLC lessened its stake in XOMA Co. (NASDAQ:XOMA - Free Report) by 31.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,704 shares of the biotechnology company's stock after selling 27,354 shares during the period. Acuitas Investments LLC owned approximately 0.52% of XOMA worth $1,595,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Geode Capital Management LLC lifted its holdings in shares of XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company's stock worth $4,840,000 after acquiring an additional 1,138 shares during the last quarter. State Street Corp raised its position in XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company's stock valued at $3,783,000 after purchasing an additional 1,754 shares in the last quarter. Barclays PLC lifted its stake in XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock worth $298,000 after purchasing an additional 8,447 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of XOMA by 18.1% in the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company's stock worth $291,000 after purchasing an additional 1,699 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 795 shares during the last quarter. Hedge funds and other institutional investors own 95.92% of the company's stock.

XOMA Trading Down 4.2 %

Shares of NASDAQ XOMA traded down $1.02 during midday trading on Friday, reaching $23.52. The company had a trading volume of 49,230 shares, compared to its average volume of 48,604. The stock has a market cap of $277.07 million, a PE ratio of -6.76 and a beta of 0.90. XOMA Co. has a one year low of $21.27 and a one year high of $35.00. The firm's fifty day moving average price is $26.30 and its 200-day moving average price is $27.93. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28.

Analyst Ratings Changes

Several brokerages have issued reports on XOMA. StockNews.com raised XOMA from a "sell" rating to a "hold" rating in a research note on Tuesday, February 11th. HC Wainwright cut their price objective on shares of XOMA from $123.00 to $104.00 and set a "buy" rating for the company in a research note on Monday, February 3rd.

Insider Activity

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business's stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 7.20% of the company's stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.